| CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) (NCT06110598) | Case Comprehensive Cancer Center | 2024-12-01 |
| Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma (NCT03811886) | Case Comprehensive Cancer Center | 2024-12-01 |
| Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer (NCT06713057) | West China Hospital | 2024-12-01 |
| Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy (NCT06722950) | Shandong New Time Pharmaceutical Co., LTD | 2024-12-01 |
| Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma (NCT06017297) | Georgetown University | 2024-12-01 |
| A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD (NCT06731959) | Aer Therapeutics | 2024-12-01 |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept (NCT06674577) | Vera Therapeutics, Inc. | 2024-12-01 |
| A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer (NCT06746870) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2024-12-01 |
| A Pilot Study of Buspirone for the Treatment of Anxiety in Youth with Autism Spectrum Disorders (NCT03432065) | Massachusetts General Hospital | 2024-12-01 |
| Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial (NCT06700798) | Fei Li | 2024-12-01 |
| HER2-PET Imaging in HER2-low Breast Cancers (NCT06732336) | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 2024-12-01 |
| A Study of RSLV-132 in Females With Sjögren's Disease (NCT06440525) | Resolve Therapeutics | 2024-12-01 |
| Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma (NCT06728618) | Shanghai Zhongshan Hospital | 2024-12-01 |
| Pharmacokinetics，Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A (NCT06656026) | Guangdong Raynovent Biotech Co., Ltd | 2024-11-30 |
| Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG) (NCT06684184) | Zhongming Qiu | 2024-11-30 |
| Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations (NCT06673290) | West China Hospital | 2024-11-30 |
| Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors (NCT06684327) | Fudan University | 2024-11-30 |
| Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer (NCT06719700) | Sun Yat-sen University | 2024-11-30 |
| ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer (NCT06052423) | Hansoh BioMedical R&D Company | 2024-11-30 |
| YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer (NCT06662669) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2024-11-30 |
| Efficacy, Safety Profile, and Post-Acne Sequelae of 0.025% Retinoic Acid Cream vs. 0.1% Adapalene Cream in Mild Acne Vulgaris in Fitzpatrick Skin Types III-V (NCT07015931) | Indonesia University | 2024-11-30 |
| Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance (NCT06634667) | Hunan Province Tumor Hospital | 2024-11-30 |
| Oral Topotecan With Toripalimab for Patients With Endometrial Cancer (NCT06548763) | Fudan University | 2024-11-30 |
| Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC (NCT06684158) | The First Affiliated Hospital with Nanjing Medical University | 2024-11-30 |
| Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT06933914) | Wuhan Createrna Science and Technology Co., Ltd | 2024-11-30 |
| A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (NCT06331598) | Hoffmann-La Roche | 2024-11-30 |
| Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence (NCT06644937) | Zhujiang Hospital | 2024-11-29 |
| Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial (NCT06126588) | Central Hospital, Nancy, France | 2024-11-29 |
| The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma (NCT06355427) | Mara Veenstra, MD | 2024-11-29 |
| Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke (NCT06696820) | Xiang Luo | 2024-11-29 |
| Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus (NCT06719024) | Hospital Authority, Hong Kong | 2024-11-29 |
| Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases (NCT06685042) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2024-11-29 |
| SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer (NCT06402435) | Hubei Cancer Hospital | 2024-11-28 |
| SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) (NCT06401005) | Hubei Cancer Hospital | 2024-11-28 |
| Evolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults (NCT06469970) | Centre Hospitalier Régional Metz-Thionville | 2024-11-28 |
| Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms (NCT06629389) | Laboratorio Elea Phoenix S.A. | 2024-11-28 |
| Loratadine for the Prevention of G-CSF-related Bone Pain (NCT05421416) | AHS Cancer Control Alberta | 2024-11-28 |
| Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) (NCT06895733) | Tianjin Medical University Second Hospital | 2024-11-27 |
| Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer (NCT06735326) | Qilu Hospital of Shandong University | 2024-11-27 |
| A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes (NCT06712680) | Sichuan Huiyu Pharmaceutical Co., Ltd | 2024-11-27 |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL (NCT06526793) | AstraZeneca | 2024-11-27 |
| Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors (NCT06630416) | Northwestern University | 2024-11-27 |
| Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC (NCT06971211) | Jianbin Bi | 2024-11-27 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas (NCT06303570) | Caliway Biopharmaceuticals Co., Ltd. | 2024-11-27 |
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies (NCT06634589) | BeOne Medicines | 2024-11-27 |
| CD70-targeted immunoPET Imaging of Kidney Cancer (NCT06680089) | RenJi Hospital | 2024-11-27 |
| Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma (NCT05647265) | Alliance for Clinical Trials in Oncology | 2024-11-27 |
| Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (NCT06428396) | Merck Sharp & Dohme LLC | 2024-11-27 |
| A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy (NCT06085625) | M.D. Anderson Cancer Center | 2024-11-26 |
| Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (NCT06236139) | Fred Hutchinson Cancer Center | 2024-11-26 |
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders (NCT06705530) | National Research Center for Hematology, Russia | 2024-11-26 |
| Comparing Moderately Ultra Hypofractionated Radiation Treatments for Prostate Cancer (NCT06409910) | University Health Network, Toronto | 2024-11-26 |
| Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study (NCT05879146) | M.D. Anderson Cancer Center | 2024-11-26 |
| BCL2i CLAG-M in R/R Acute Myeloid Leukemia (NCT06660368) | H. Lee Moffitt Cancer Center and Research Institute | 2024-11-26 |
| Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy (NCT06552572) | Samsung Medical Center | 2024-11-26 |
| A Study of Tetrathiomolybdate (TM) Plus Capecitabine (NCT06134375) | Dartmouth-Hitchcock Medical Center | 2024-11-26 |
| Tirzepatide Weight Loss for MRD+ Early Breast Cancer (NCT06517212) | Baylor Research Institute | 2024-11-26 |
| Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma (NCT06645678) | YOUNGIL KOH | 2024-11-26 |
| Study of Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Medicinal Product MediReg® (NCT06869863) | Lomonosov Moscow State University Medical Research and Educational Center | 2024-11-26 |
| A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials (NCT06736262) | Jasper Therapeutics, Inc. | 2024-11-26 |
| Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD (NCT06672536) | Sinocelltech Ltd. | 2024-11-26 |
| Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. (NCT06763965) | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | 2024-11-26 |
| Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment (NCT06662877) | Sun Yat-sen University | 2024-11-25 |
| Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET (NCT06758882) | Marco Oderda | 2024-11-25 |
| NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL (NCT06737250) | NOBO Medicine | 2024-11-25 |
| Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas (NCT06687681) | Marzieh Ebrahimi | 2024-11-25 |
| A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib (NCT06668103) | Abbisko Therapeutics Co, Ltd | 2024-11-25 |
| Evaluating an rhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing (NCT06632418) | Alexander Hawkins | 2024-11-25 |
| A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers (NCT06422403) | National University Hospital, Singapore | 2024-11-25 |
| HEALSea Nasal Spray for Prevention of Infections in Children (NCT06582589) | Lallemand Pharma AG | 2024-11-25 |
| Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS (NCT07095712) | n-Lorem Foundation | 2024-11-25 |
| Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD (NCT04882839) | Beersheva Mental Health Center | 2024-11-25 |
| Renal Retention in High Grade Upper Tract Urothelial Cancer (NCT05656235) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2024-11-25 |
| Study to ONO-4538 in Patients With Rhabdoid Tumor (NCT06622941) | Ono Pharmaceutical Co., Ltd. | 2024-11-25 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants (NCT06720038) | Vaxcyte, Inc. | 2024-11-25 |
| A Study of ES014 in Subjects With Advanced Solid Tumors (NCT06543056) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-11-25 |
| Effectiveness of Penthrox vs Placebo in Sinus Procedures, a Clinical Trial (NCT06750302) | St. Paul's Hospital, Canada | 2024-11-24 |
| Study SOLACE SEPSIS (NCT06634069) | University Hospital Pilsen | 2024-11-24 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases (NCT06688799) | Beijing GoBroad Hospital | 2024-11-23 |
| Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia (NCT07370922) | Ain Shams University | 2024-11-22 |
| A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (NCT06647498) | Washington University School of Medicine | 2024-11-22 |
| Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer (NCT06598033) | Fudan University | 2024-11-22 |
| A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (NCT05552157) | Washington University School of Medicine | 2024-11-22 |
| A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment (NCT06668805) | BioMarin Pharmaceutical | 2024-11-22 |
| Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients. (NCT06731738) | IC TARGETS AS | 2024-11-22 |
| Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients (NCT06800391) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2024-11-22 |
| A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration (NCT06959615) | Jacobio Pharmaceuticals Co., Ltd. | 2024-11-22 |
| Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma (NCT06341712) | Ipsen | 2024-11-22 |
| Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer (NCT06601283) | Fudan University | 2024-11-22 |
| Contribution of PET/CT With Gallium 68 Citrate (68Ga-PET/CT) for the Diagnosis of Prosthetic Valve Infective Endocarditis (NCT05446376) | University Hospital, Bordeaux | 2024-11-22 |
| EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source (NCT06715449) | University of East Anglia | 2024-11-22 |
| A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis (NCT03160430) | Resverlogix Corp | 2024-11-22 |
| Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma (NCT06448026) | M.D. Anderson Cancer Center | 2024-11-21 |
| Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms (NCT06484075) | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 2024-11-21 |
| Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic (NCT06226610) | Akron Children's Hospital | 2024-11-21 |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder (NCT06701903) | Intra-Cellular Therapies, Inc. | 2024-11-21 |
| A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration (NCT06660667) | Sanofi | 2024-11-21 |
| Evaluation of the Decolonization Rate and Acceptance of a Complete Nasal Decolonization Kit With Povidone Iodine for MRSA Patients (NCT05696132) | Nantes University Hospital | 2024-11-21 |
| A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors (NCT06598371) | M.D. Anderson Cancer Center | 2024-11-21 |
| Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization (NCT06435845) | Rallybio | 2024-11-21 |